As previously reported, Piper Sandler upgraded ImmunoGen to Overweight from Neutral with a price target of $16, up from $6, following what the firm calls "overwhelmingly positive topline data" from the confirmatory MIRASOL trial evaluating the safety and efficacy of Elahere compared to chemotherapy in patients with folate receptor alpha-positive platinum-resistant ovarian cancer. While noting that full data are expected to be presented at a medical meeting later this year, Piper argues that "it is hard not to declare this topline an emphatically clean win for Elahere" and it feels comfortable there is opportunity for further upside as near-term estimates are "still likely too low."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMGN:
- ImmunoGen Skyrockets after Positive Topline Data
- ImmunoGen’s MIRASOL trial results represent best-case scenario, says Guggenheim
- ImmunoGen reports ‘positive’ results from Phase 3 MIRASOL trial
- ImmunoGen Rockets Up on Great Sales, Earnings
- ImmunoGen raises FY23 revenue excluding ELAHERE view to $45M-$50M